VAIOMER
  • VAIOMER
    • About VAIOMER
    • Contamination-aware approach
    • Microbiome discovery timeline
    • Microbiome analysis services
    • News
  • ABOUT MICROBIOME
    • Definitions
    • Translational research
    • Bacterial translocation
    • Atlas of microbiomes
  • MICROBIOME APPLICATIONS
    • Cardio-metabolic diseases
    • Liver diseases
    • Gastrointestinal disorders
    • Cancer
    • Neurodegenerative and mental disorders
    • COVID & Infectious diseases
    • Autoimmune and inflammatory diseases
    • Nutrition
    • Kidney diseases
    • Microbiome in early life
  • RESOURCES
  • CONTACT
  • #
  • #
Select Page
Vaiomer will be attending «Journées Polepharma de Microbiomique, 4ème édition»

Vaiomer will be attending «Journées Polepharma de Microbiomique, 4ème édition»

by microbiome | Nov 16, 2023 | Highlights, News

Vaiomer is happy to announce that we will take part in the 4th edition of « Journées Polepharma De Microbiomique » on November 22 & 23 in Rouen, FRANCE.   Vaiomer is honored to introduce the amazing “Microbiota and Cancer” session on the 4th...
Vaiomer is taking part to « 7èmes JOURNEES SCIENTIFIQUES FRANCOPHONES du CALM»

Vaiomer is taking part to « 7èmes JOURNEES SCIENTIFIQUES FRANCOPHONES du CALM»

by microbiome | Nov 9, 2023 | Highlights, News

Vaiomer is happy to announce its participation to “7èmes JOURNEES SCIENTIFIQUES FRANCOPHONES du Club Alzheimer de Montpellier’’ on November 14&15”. Vaiomer is excited to exchange and share new ideas with scientists and academics in the field of...
Vaiomer is participating in the Genotoul Scientific Day-HOLOBIONTES

Vaiomer is participating in the Genotoul Scientific Day-HOLOBIONTES

by microbiome | Nov 6, 2023 | Highlights, News

Vaiomer is happy to announce that we will be participating in the “Genotoul Scientific Day: HOLOBIONTES Understanding host-microbiota interactions” on Thursday, November 9, 2023 in Toulouse, FRANCE We are looking forward to exchange on advanced concepts in ...
Probiotic strains translocate to the tumor and improve ICI efficacy through indole-3-aldehyde release

Probiotic strains translocate to the tumor and improve ICI efficacy through indole-3-aldehyde release

by microbiome | Oct 5, 2023 | Highlights, Microbiomes & cancer, Vaiomer original work

DOI: 10.1016/j.cell.2023.03.011 In recent years, several studies have shown the importance of both the gut and the tumor microbiome in cancer progression and immune checkpoint inhibitors (ICI) response. Thus, microbiomes appear as a new source of therapeutic...
The human tumor microenvironment is colonized by cancer type–specific bacteria and fungi

The human tumor microenvironment is colonized by cancer type–specific bacteria and fungi

by microbiome | Sep 22, 2023 | Highlights, Microbiomes & cancer, Vaiomer original work

DOI N°1: 10.1126/science.aay9189 DOI N° 2: 10.1016/j.cell.2022.09.005 Several studies have shown the importance of the gut microbiota in cancer progression and treatment response. Although bacteria were first detected in human tumors more than 100 years ago, the tumor...
« Older Entries

Research

Categorie

  • Highlights (31)
  • Microbiomes & cancer (5)
  • Microbiomes & Metabolism (9)
  • News (15)
  • Vaiomer original work (16)

Archives

  • Vaiomer will be attending «Journées Polepharma de Microbiomique, 4ème édition»
  • Vaiomer is taking part to « 7èmes JOURNEES SCIENTIFIQUES FRANCOPHONES du CALM»
  • Vaiomer is participating in the Genotoul Scientific Day-HOLOBIONTES
  • Probiotic strains translocate to the tumor and improve ICI efficacy through indole-3-aldehyde release
  • The human tumor microenvironment is colonized by cancer type–specific bacteria and fungi

516, rue Pierre et Marie Curie
31670 Labège, France
Tel : +33 (0)5 61 28 71 66
Fax : +33 (0)5 61 28 71 68
Contact us !

 

About Vaiomer :

Vaiomer microbiome studies and expert service supports your discoveries and innovations when identifying predictors and mechanisms associated with the development of chronic diseases.

 

Follow us !

Vaiomer ©  – Legal Notice and Privacy Policy and GDPR conditions– Conception by Comm’IN

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok